Life Sciences Research and Analysis

1. The race intensifies for a COVID-19 vaccine as hope builds for emergency approval by September

   29 April 2020 Margaret Labban, Ph.D.

   While the Oxford group's vaccine appears to be one of the leading candidates currently in development, several factors could affect the candidate’s...

   

2. Is the US ready to start relaxing COVID-19 lockdowns?

   24 April 2020 Sacha Baggili, B.A, M.A Margaret Labban, Ph.D.

   US guidelines for opening up again converge with WHO guidelines, but set a lower bar for starting relaxations

   

3. COVID-19 could cause delays for price framework agreements in parts of Europe

   21 April 2020 Mr. Eoin Ryan

   Could national healthcare emergencies delay price framework agreements in parts of Europe?

   

4. US scrambles for resources in COVID-19 response

   30 March 2020 Gustav Ando

   Resource issues underscore the importance of international trade for medical supplies

   

5. COVID-19: Risk of severe complications among the United States health workforce

   20 March 2020 Tim Dall

   Health workers on front lines treating people with COVID-19 are at high risk -- what changes are needed?

   

6. COVID-19 pandemic: Health system surge capacity

   19 March 2020 Milena Izmirlieva

   Countries have inadequate health system surge capacity to deal with COVID-19 pandemic

   

7. UK bans parallel export of two COVID-19 treatment candidates to protect national supply

   26 February 2020 Janet Beal

   As the UK government steps up its preparedness plan for any national spread of the COVID-19 outbreak, it has suspended parallel export for two...

   

8. China’s young biosimilars sector

   27 December 2019 Sophie Cairns

   China’s young biosimilars market is taking off, with a raft of approvals of domestically-developed biosimilars expected in the next few years....

   

9. Polish pharma associations unite in appeal for greater access to biologics

   18 December 2019 Brendan Melck

   New originator biologics are being added to the reimbursement list in Poland, but they are simply not reaching a sufficient number of patients....

   

10. How to democratize access and prevent the next supermodel medicine

    11 December 2019 Tania Rodrigues

    Discussions around collaboration and precision medicines from ISPOR Europe

    

11. Risks to UK pharmaceutical spending from a US-UK free trade deal

    02 December 2019 Milena Izmirlieva

    Danger for UK healthcare spending may not be from rising drugs prices or from reducing the ability of the NHS to negotiate drug prices but from...

    

12. Challenges with risk sharing in Eastern Europe raised at ISPOR Europe meeting

    04 November 2019 Milena Izmirlieva

    Insights from ISPOR 2019: Challenges that payers in Central and Eastern European (CEE) countries face when trying to devise risk sharing agreement...

    

13. Germany’s fixed pricing for medicines faces European reckoning

    04 November 2019 Brendan Melck

    Germany’s health minister Jen Spahn is seeking to resolve a long-running dispute with the European Commission over fixed drug pricing rules

    

14. Dynamic reform in International Reference Pricing

    30 October 2019 Tania Rodrigues

    Slovakia approved legislation to curtail alleged manufacturer attempts to circumvent IRP-related price reductions by marketing unique presentations...

    

15. Ten-year Medicare budget impact of increased coverage for anti-obesity intervention

    02 October 2019 Frank Chen

    Expanding Medicare coverage to both lifestyle interventions and medication could lead to long-term reductions in health care spending.

    

16. South Korean pharma dreams struggle

    01 October 2019 Sophie Cairns

    South Korean drug makers have seen several high-profile setbacks in recent months. What does this mean for overseas pharma?

    

17. The economic burden of elevated blood glucose levels in 2017 in the United States

    26 September 2019 Will Iacobucci Tim Dall April Semilla

    The total economic burden associated with elevated blood glucose levels in the United States reached nearly $404 billion in 2017

    

18. Taking the pulse of international reference pricing

    12 August 2019 Cameron Lockwood

    Alive and kicking, this policy tool continues to feature prominently in the pricing framework of many markets, mature and emerging alike.

    

19. Irish green credentials fail on pharmaceutical waste exports

    02 August 2019 Eoin Ryan

    Ireland's high level of pharma waste exports - rather than dealing with the problem at source - prompts Takeda's call for infrastructure investment...

    

20. Canada makes history in basketball and Pharmacare

    19 June 2019 Margaret Labban

    Following the developments of Pharmacare in Canada as it breaks new ground with a universal, publicly-funded drug plan

    

21. Inconsistent application of pricing policies in China contributes to pockets of high prices

    17 June 2019 Sophie Cairns

    Despite China’s efforts to rein in drug prices, pockets of high prices persist.

    

22. Argentina announces innovative reimbursement deal for Spinraza

    30 May 2019 Ewa Oliveira da Silva

    Argentina's recent reimbursement deal with Biogen is of note for manufacturers of other high-cost therapies

    

23. Laying the Foundations of Pharmacare in Canada

    17 May 2019 Margaret Labban

    Spend 2 minutes with our analyst, Margaret Labban, on Pharmacare

    

24. New payment-by-results and payback regulations for Bulgaria

    17 May 2019 Brendan Melck

    Bulgaria's new P&R policies are a double blow to the pharma industry

    

25. Zolgensma may be a potential game-changer for SMA

    03 May 2019 Janet Beal

    As a new one-off gene therapy for SMA nears the US market, effective pricing will be crucial in ensuring sustainable patient access.

    

26. India issues new clinical trial rules to expedite new drug approvals

    17 April 2019 Sacha Baggili

    India's new clinical trial rules establish an accelerated pathway for new drug approvals, but affordability remains a barrier to access.

    

27. Medicare X

    12 April 2019 Milena Izmirlieva

    Democrats explore creative ways to expand health insurance access with Medicare X

    

28. Pharmacare for all in Canada: Unlikely proposal to imminent threat

    02 April 2019 Margaret Labban

    The creation of the Canadian Drug Agency and Pharmacare could mean big changes for drug prices

    

29. Accuracy check: Norwegian health expenditure data

    29 March 2019 Eoin Ryan

    Norway’s Statistik Sentralbyrå (SSB) annual healthcare and pharmaceutical expenditure statistics confirms the accuracy of IHS Markit’s healthcare...

    

30. Budget impact of passing a share of negotiated manufacturer rebates to patients at POS

    12 March 2019

    Using our model we examine the budget impact of passing through a share of negotiated manufacturer rebates to patients at POS

    

31. United States experience dramatic shift in public share of healthcare spending

    12 February 2019 Milena Izmirlieva

    Our latest quarterly forecast, released in January 2019, indicates that public spending in the United States will account for more than 86% of...

    

32. Population health outcomes of American patients under different drug access conditions

    28 December 2018 Cameron Lockwood

    Significant discrepancies remain between the access conditions of different countries

    

33. Improving Access to Medication-Assisted Treatment for Opioid Use Disorder among the Commercially-insured US Population

    13 December 2018 Frank Chen April Semilla

    Using a published and validated microsimulation model, we predicted the annual number of overdose, mortality, and direct medical costs associated...

    

34. Humira faces up to intense biosimilar competition

    28 November 2018 Praful Mehta Eoin Ryan

    Tenders for biosimilars for Humira in both Denmark and Italy mark a dramatic shift

    

35. 2018 ISPOR Europe research on IRP

    14 November 2018 Cameron Lockwood

    International reference pricing of pharmaceuticals: Apply liberally or use sparingly?

    

36. Our pricing and reimbursement research presented at ISPOR Europe

    14 November 2018 Milena Izmirlieva

    The impact of expedited marketing authorisation on P&R outcomes for drugs in the US and EU-5

    

37. ISPOR Europe 2018 Barcelona

    12 November 2018 Gustav Ando

    Meet us at ISPOR, come see our posters, chat with us about our new product innovations

    

38. Rapid changes in the global IRP environment

    08 November 2018 Gustav Ando

    US gets the headlines, but Greece and Denmark have more immediate impact

    

39. Mexico facing smaller healthcare tender due to double procurement needs

    06 November 2018 Ewa Oliveira da Silva

    Inefficiency in the centralized model behind Mexico's tendering decline

    

40. Medical supplies to Czech hospitals to be stopped after call to reveal drug prices in tenders

    17 October 2018 Brendan Melck

    Discounts provided to Czech state hospitals in tenders showed that manufacturers are offering discounts on that reduce the ultimate price to...

    

41. Italian pharma tendering set for new oversight in two-year outlook

    08 October 2018 Eoin Ryan

    The co-ruling Five Star Movement (Movimento Cinque Stelle: M5S) has voiced criticism of the economic case for pharmaceutical tenders in Italy...

    

42. Norwegian pharma industry calls for tendering and IRP reforms

    05 October 2018 Eoin Ryan

    To curb shortages, Norway's pharma industry turns to a number of mechanisms to ensure that the country maintains low drug prices in relation...

    

43. UK post-Brexit participation in unified patent court poses plenty of questions

    28 September 2018 Eoin Ryan

    If UK and EU negotiators are unable to conclude a withdrawal and transition agreement, the likelihood of UK participation in the UPC and unitary...

    

44. HTA adoption in Asian emerging pharma markets

    27 September 2018 Sophie Cairns

    Asia’s emerging pharmaceutical markets are likely to focus increasingly on Health Technology Assessment as healthcare costs rise.

    

45. Regulatory convergence or divergence for Asian pharma

    20 September 2018 Sophie Cairns

    Insights from The Pharma Market Access and Pricing Summit Asia

    

46. Is healthcare reform in the cards with new socialist government in Spain

    16 August 2018 Ewa Oliveira da Silva

    Policy uncertainty is set to remain high as the government may struggle to pass major reforms

    

47. Culture shift at Takeda a sign of things to come

    10 July 2018 Sophie Cairns

    Takeda’s proposed purchase of Shire has led to shareholder dissent; however, M&A is expected to continu

    

48. Nevermore ignore the role of digital health in health decision making

    22 May 2018 Gustav Ando

    Insights from ISPOR Baltimore 2018 - digital health

    

49. ISPOR 2018 Baltimore

    18 May 2018 Gustav Ando

    Meet us at ISPOR, come see our posters, chat with us about our new product innovations

    

50. Drug supply shortages in Germany

    17 May 2018 Brendan Melck

    Will shortages lead to changes in the discount-contract system?

    

51. Impact of passing through rebates at the POS for diabetes medicines

    11 May 2018

    Passing through a portion of rebates could generate substantial savings across the entire Medicare program

    

52. US tariffs likely to mostly affect US generics makers

    19 April 2018 Sophie Cairns

    Proposed tariffs on Chinese-made goods, including pharmaceutical ingredients, are expected to affect mainly US generics makers.

    

53. The economic impact of diagnosed diabetes

    27 March 2018 Ritashree Chakrabarti Tim Dall

    Updates to the previous estimates on the burden of disease

    

54. Barricading the front door: A look at Colombia’s moves toward value-based pricing

    26 March 2018 Tania Rodrigues

    Colombia embraces value-based pricing with Decree 433 of 2018 for new innovative drugs at market entry

    

55. Risk-sharing as a path forward for Mexico

    14 March 2018 Ewa Oliveira da Silva

    Is risk-sharing the way forward for this cash-strapped public healthcare system?

    

56. On the road to HTA harmonization in Europe

    28 February 2018 Eoin Ryan

    Reforms face a difficult path to implementation and the real possibility that they may require careful modification.

    

57. The impact of Medicare coverage for anti-obesity interventions

    07 December 2017

    Over the next 10 years, Medicare is expected to save $19 billion

    

58. National Academies report adds fuel to fire in raging US drug pricing debates

    04 December 2017 Milena Izmirlieva

    Consumer access to effective and affordable medicines in the US is currently inadequately served by the pharmaceutical sector

    

59. Amsterdam triumphs: Is the Netherlands a Trojan horse for pricing and drug approval reform in Europe?

    28 November 2017 Eoin Ryan

    Luring the EMA to Amsterdam marks a stunning diplomatic coup

    

60. Will Argentina's public healthcare reform finally accelerate?

    14 November 2017 Ewa Oliveira da Silva

    After October election strengthens government will public healthcare reform see a change?

    

61. Value in healthcare: Insights from ISPOR

    13 November 2017 Anne-Charlotte Ackermann

    A value-based approach or a cost-effectiveness or efficacy approach?

    

62. Better diabetes treatment can save Medicaid over $4 billion per year

    09 November 2017 Frank Chen

    State-by-state projected annual savings to Medicaid from better management of diabetes

    

63. So, was this worth the wait?…the UK government finally responds to last year's Accelerated Access Review

    03 November 2017 Janet Beal

    The UK government has issued its much-anticipated response to the Accelerated Access Review (AAR)

    

64. Visit us at ISPOR 2017 Glasgow!

    01 November 2017 Gustav Ando

    Meet with our experts and analysts in Glasgow next week

    

65. China's new clinical trial regulations a win-win for all

    23 October 2017 Sophie Cairns

    China removes the requirement for local clinical data as part of the drug approval process

    

66. Time for a consultation on the impact of Brexit on the UK's access to medicines: Better late than never?

    18 October 2017 Janet Beal

    UK access to medicines during and after Brexit

    

67. New import substitution initiatives in the Middle East – 2017, the year of new policies

    16 October 2017

    A close look at pharma strategy in the Middle East

    

68. International Reference Pricing expands reach in leading Latin American countries

    28 September 2017 Tania Rodrigues

    A look at how the formal use of IRP is evolving in Brazil compared to Colombia.

    

69. Lithuania's drug cost-containment initiatives – getting tough on pricing

    12 September 2017 Brendan Melck

    How does Lithuania plan to reducethe cost of medicines?

    

70. Spain bets on Barcelona to get the EMA as the independence movement in Catalonia reaches climax

    29 August 2017 Ewa Oliveira da Silva

    Where will the EMA locate after Brexit? Can Spain be the answer?

    

71. IRP rumblings: An eclipse of traditional market access strategy?

    17 August 2017 Cameron Lockwood

    Is IRP a self sustaining dynamo or soon to be eclipsed?

    

72. In China drugmakers walk increasingly fine line between lower prices and making a buck

    04 August 2017 Sophie Cairns

    China adds another 36 medicines to NRDL

    

73. What next for US healthcare reform as Senate fails to pass ACA repeal bill?

    28 July 2017 Milena Izmirlieva

    What was the "Skinny Bill" and what's next?

    

74. IRP is dead, long live IRP

    18 July 2017 Cameron Lockwood

    At what point will payers decide that opacity in the prices being referenced renders the tool meaningless?

    

75. The spread of counterfeit pharmaceuticals across the Middle East poses threats for pharma

    11 July 2017

    Drug shortages and the insufficient control systems in many Middle East countries have also allowed illegal mega-manufacturing factories to work...

    

76. Pricing analytics: Next frontier for linking pricing and HTA data

    16 June 2017 Praful Mehta

    IHS Markit and Context Matters have for the first time combined these two diverse datasets under one platform so that companies can draw meaningful...

    

77. Outcry over patient death puts Hong Kong's drug reimbursement system into spotlight

    08 June 2017 Sophie Cairns

    There is increasing public debate over whether Hong Kong's cash-rich government should give more public funding to rare rare-disease medicines....

    

78. The politics of oil wreak havoc on access to medicines

    31 May 2017 Milena Izmirlieva

    How oil prices undermine a country's ability to pay for medicines

    

79. US healthcare reform: Caught between a rock and a hard place

    24 May 2017 Margaret Labban

    A deeper look at US healthcare reform

    

80. US Healthcare Reform: The ISPOR Debate

    23 May 2017 Gustav Ando

    Insights from Day one at ISPOR Boston: US healthcare reform

    

81. Meet us at ISPOR Boston – Booth 204

    22 May 2017 Gustav Ando

    IHS Markit's life sciences team is at ISPOR this week.

    

82. Can Affordable Medicines become a reality for Ukraine?

    10 May 2017 Janet Beal

    Ukraine has remained the only European country where until very recently patients have largely had to pay out-of-pocket

    

83. Austria: Hastily implemented legal changes hit pharma industry

    03 May 2017 Brendan Melck

    Tensions between the pharmaceutical industry and the social security institutions in Austria are high again

    

84. Nordics inch toward cooperation on drug purchasing, but don't expect early developments

    13 April 2017 Eoin Ryan

    The latest analysis could facilitate future cross-border procurement structures between two or more Nordic countries

    

85. International reference pricing: Love it or hate it, there is a good way and a bad way to do it

    27 March 2017 Tania Rodrigues

    best IRP practice considerations from an industry standpoint

    

86. Cross-country procurement: Will it soon be the bane of pharma's existence?

    21 March 2017 Milena Izmirlieva

    A look at some of the developments in cross-country procurement and its possible negative impact for Industry

    

87. Three trends that will shape EU market access in the next decade

    17 March 2017 Praful Mehta

    There are clear signals in the EU that the market access environment will become more stringent in the coming years

    

88. Pharmaceutical pricing reform efforts in California: Poking the bear in the Grizzly State

    10 March 2017 Cameron Lockwood

    A look at SB-17 and what it means for drug pricing in CA

    

89. Could drug pricing legislation be championed by US President Trump?

    06 March 2017 Margaret Labban

    The five key principles that need to be present in new legislation that would replace the ACA

    

90. Comparing health outcomes and pharma pricing around the world: A PISA for healthcare is a health minister's worst nightmare…

    24 January 2017 Gustav Ando

    The Patient Reported Indicators Survey (PaRIS) was formally launched with the ambition of becoming the pre-eminent standard to measure quality...

    

91. Hurdles encountered in transferability of health economic evidence to middle- and low-income countries

    05 January 2017 Tania Rodrigues

    A survey of heads of HTA agencies in middle-income countries in Central and Eastern Europe (CEE), Latin America and Asia showed reservations...

    

92. Two sides of the same coin: National health economic guidelines in Italy and Portugal

    28 December 2016 Tania Rodrigues

    Whilst at ISPOR Vienna, I attended a lively session on national health economic guidelines in Southern Europe that highlighted how current practice...

    

93. Big dreams versus cost-saving schemes – will the UK dare to pursue its Accelerated Access ambitions in cash-strapped times?

    18 November 2016 Janet Beal

    A deeper look at the UK's Accelerated Access Review

    

94. The Access to Medicine Index 2016: Highlighting the role for tiered pricing

    14 November 2016 Cameron Lockwood

    An independent assessment of what the pharmaceutical industry is doing to help make medicines more accessible in low- and middle-income countries...

    

95. Trumping Obamacare may be on the cards

    11 November 2016 Milena Izmirlieva

    Early expectations for the pharmaceutical industry as a result of the Trump election.

    

96. The Other vote today – Will the future of US drug pricing be decided? Will we see interstate parallel imports and interstate reference pricing?

    08 November 2016 Gustav Ando

    Proposition 61 on today's California ballot

    

97. Where there isn't a will, there isn't a way – Obstacles to differential pricing

    01 November 2016 Gustav Ando

    Insights from 19th annual European Congress of ISPORin Vienna

    

98. Proposed HTA agency AGNETS: The creation of a fourth hurdle in Argentina?

    28 October 2016 Tania Rodrigues

    President Mauricio Macri's bill for the creation of a formal HTA agency

    

99. Through the comparative effectiveness research lens: US, European payers have a taste for real world trials

    26 October 2016 Tania Rodrigues

    Education on rising drug costs

    

100. Japan hints at potential exodus of pharmaceutical companies from post-Brexit London

     14 September 2016 Sophie Cairns

     Japan's Ministry of Foreign Affairs issued an unusually direct warning of "great turmoil" in a post-Brexit scenario

     

101. Deepening European ties: A look at the potential impact of recent IRP changes in Ireland

     09 September 2016 Eoin Ryan

     Ireland's IRP framework underwent a major shake-up in August including an expansion of the basket

     

102. Changes to AMNOG in the Pharmaceutical Care Strengthening Act

     06 September 2016 Brendan Melck

     industry fears hit from reimbursement restrictions

     

103. Abu Dhabi private health centers at risk of closure due to new insurance scheme

     02 September 2016 IHS Markit Life Sciences Expert

     The new insurance scheme may have negative effects for critically ill-patient groups.

     

104. Pharma industry embraces Medicines Patent Pool's voluntary licence

     19 August 2016 Angelica Kershaw

     Public health experts have welcomed the new approach of some pharmaceutical companies towards unveiling new patent policies facilitating access...

     

105. 20 kilobases closer: A course correction for molecular diagnostics in Germany

     15 August 2016 Cameron Lockwood

     The field of advanced molecular diagnostics, including next-generation sequencing (NGS), has had a complicated history in Germany. When we performed...

     

106. New Zealand's Pharmac finally reimburses Keytruda, to cancer groups' delight and disgust

     01 August 2016 Sophie Cairns

     A win that is bittersweet

     

107. Cutaneous leishmaniasis sweeps across Middle East

     28 July 2016 IHS Markit Life Sciences Expert

     The people of Syria are now facing the spread of the serious but non-lethal skin infection

     

108. Brexit impact on healthcare: A lot of cloud and no silver lining

     19 July 2016 Milena Izmirlieva

     Pinpointing the exact impact of Brexit on healthcare spending and pharmaceutical spending remains a moving target

     

109. Inaction on hospital drug spending ruffles EC feathers as fresh political deadlock likely in Spain

     18 July 2016 Tania Rodrigues

     The Spanish health sector is awaiting the formation of a coalition government that will help navigate a complex multi-party regional political...

     

110. Sweden, Denmark and Italy offer to host EMA headquarters in the event relocation is necessary

     11 July 2016 Eoin Ryan

     Major economic and political uncertainty across both UK and EU markets is likely to hamper the EMAs relocation and complicate the decision

     

111. Latin America – the going gets tough

     08 July 2016 Jing Zhang

     What is the economic health of South America for pharma?

     

112. Liquid biopsies: The next wave of cancer screening

     06 July 2016 Cecilia Chui

     Immunotherapy and precision medicine centre-stage at ASCO

     

113. Launch in the time of cost containment: How are European countries positioned to fund emerging breakthroughs in oncology?

     30 June 2016 Cameron Lockwood

     Question marks over the sustainability of industry pipelines have been replaced by question marks over the sustainability of healthcare systems...

     

114. Colombia's MoH vs Novartis

     27 June 2016 Angelica Kershaw

     Resolution 2475/2016 authorises the Inter-ministerial Medicines and Medical Devices Pricing Commission (CNPMD) to reduce Glivec's price.

     

115. A vote to leave the European Union and what it would mean for Britain's place in the world of pharma

     20 June 2016 Milena Izmirlieva

     As the date for Great Britain's referendum on whether to leave the European Union approaches, the pre-referendum debates have only marginally...

     

116. Budget impact in France: A new key to market access

     17 June 2016 Anne-Charlotte Ackermann

     A close look at France's formal BIA and access to HCV meds

     

117. NICE's proposed Abbreviated Technology Appraisal scheme

     14 June 2016 Janet Beal

     A cheaper, faster track to approve funding for me-too medicines in the UK?

     

118. Greek pharma industry unites against growing burden of clawback

     10 June 2016 Brendan Melck

     A familiar problem in Greece today: trying to implement reforms which are difficult enough to implement in normal circumstances...

     

119. Notes from the road: Insights from our latest trip to Asia

     01 June 2016 Sophie Cairns

     Pricing and cost-effectiveness and public hospital discussions from our trip to Asia

     

120. Who's paying for precision medicine? A look at molecular diagnostic commissioning policy in the UK

     26 May 2016 Cameron Lockwood

     A look at some of the challenges facing the NHS commissioning framework for molecular diagnostic testing

     

121. From tiered pricing to tiered IP: The evolving access to medicines landscape

     23 May 2016 Cameron Lockwood

     AA closer look at the access-to-medicines debate

     

122. Access our insights: Life Sciences MCS content now available on the IHS Online Store

     18 May 2016 Cameron Lockwood

     A new and easy way to access our multi client studies

     

123. The spread of the Zika threat and the response of the global pharma industry – parallels to Ebola but important distinctions

     21 April 2016 Angelica Kershaw

     The latest on the spread of Zika and developments to address the current outbreak

     

124. New energy is injected into DRG-based hospital payments

     22 March 2016 Tania Rodrigues

     A close look at the recent developments with DRGs

     

125. Cost driver or cost saver? Obama's take on precision medicine

     06 March 2016 Cameron Lockwood

     In late February, the Obama administration announced a number of actions designed to accelerate the development of precision medicine in the...

     

126. Pharmaceutical industry gears up for data disclosure on payments to healthcare professionals

     29 February 2016 Eoin Ryan

     The new EFPIA code introduces a significant new level of public scrutiny

     

127. HAS of cards: Looking for the new president of France's High Health Authority

     02 February 2016 Choukri Genane

     A close look at the proposed appointment of haematology specialist Buzyn Agnes

     

128. Complexities in personalised medicine: Key to new directions in oncology

     10 January 2016 Cecilia Chui

     A closer look at precision Meds

     

129. China's economy and prospects of TCM

     03 January 2016 Zhang, Jing

     Understanding Chinese traditional medicine

     

130. Taiwan's pharmaceutical market, as it is preparing to join TPP in the second round

     27 December 2015 Zhang, Jing

     Understanding the twentieth-largest pharmaceutical market in the world

     

131. OTC in CEE: A way out of the regulatory jungle

     21 December 2015 Brendan Melck

     How over the counter meds are changing the market landscape

     

132. US ICER: What can we learn from the first completed review?

     10 December 2015 Milena Izmirlieva

     A look at the pricing for PCSK9 inhibitors for cholesterol

     

133. Impact of dual pricing on pharmaceuticals in Spain

     07 December 2015 Floriane Reinaud

     Options when the price requested by the pharmaceutical company is believed to be too high

     

134. Why the TPP is good news for foreign drugmakers in Vietnam

     02 December 2015 Sophie Cairns

     Vietnam's pharmaceutical sector is expected to see the fiercest competition

     

135. Time to start living in the real world: Does Sweden's untapped goldmine hold the answers?

     30 November 2015 Maria McGee

     Time and again when we explore ways in which we can streamline market access, secure reimbursement and even refine pharmaceutical pricing, we...

     

136. Political dimensions of the $160 billion Viagra-Botox merger

     23 November 2015 Gustav Ando

     Insights on the Pfizer/ Allergan merger

     

137. Poland's new government – what prospects for healthcare?

     19 November 2015 Brendan Melck

     What are the implications for healthcare following the elections?

     

138. Parallel scientific advice: Diverging views and challenges

     17 November 2015 Milena Izmirlieva

     Insights from ISPOR Milan - parallel scientific advice by regulatory agencies and HTA agencies

     

139. The slow death of the Egyptian pharmaceutical market

     15 November 2015 Gustav Ando

     A healthcare system in crisis, a pharmaceutical industry in decline, and acute shortages of essential medicines

     

140. Managed entry agreements: Insights from ISPOR Europe meeting

     13 November 2015 Milena Izmirlieva

     Insights from ISPOR Milan 2015 on managed entry agreements

     

141. The cross currents at play in the Brazilian retail pharmacy market

     10 November 2015 Tania Rodrigues

     Discounts usually offered to distributors and retailers will be slashed

     

142. A jagged little pill – ISPOR turns 20, HTA looks to the future

     09 November 2015 Gustav Ando

     Insights from ISPOR Milan

     

143. Cancer Drugs Fund: To be or not to be?

     08 November 2015 Kavita Rainova

     Is England's Cancer Drug Fund sustainable?

     

144. Clinical utility: An imprecise construct at the heart of precision medicine

     04 November 2015 Cameron Lockwood

     The value of molecular testing will increasingly hinge on experimental demonstration of clinical utility

     

145. Ireland's High-Tech Drugs scheme faces funding threat

     03 November 2015 Eoin Ryan

     Ongoing price reductions negotiations covering the supply of innovative medicines

     

146. Visit us at ISPOR 2015 Milan! Booth 1015

     30 October 2015 Gustav Ando

     Booth 1015 and during session 3 of research posters

     

147. LAtAm HTA harmonisation and centralised procurements: A feasible possibility?

     26 October 2015 Angelica Kershaw

     Insights from ISPOR Latin America on HTA and centralized procurement

     

148. Psst – Hey buddy, wanna buy some cheap Sovaldi?

     20 October 2015 Sophie Cairns

     In Hong Kong's flourishing black market, costly branded drugs can be bought at a fraction of their market price

     

149. AstraZeneca's most recent investments in biomarker research in Sweden: Staying true to its roots

     13 October 2015 Maria McGee

     A close look at AstraZeneca´s most recent biomarker technology collaboration

     

150. France's 2016 Social Security Financing Act: A figure is worth a thousand words

     09 October 2015 Choukri Genane

     A look at the ongoing struggle for the French government with its health deficit

     

151. Pharma strikes strategic bench- to-bedside precision medicine collaborations in Spain

     05 October 2015 Tania Rodrigues

     The state of precision medicine in Spain

     

152. Two cases of polio confirmed in Ukraine- first cases in Europe since 2010

     14 September 2015 Kavita Rainova

     The vaccines situation raises concerns over the potential rise in other vaccine-preventable diseases

     

153. An all encompassing market access strategy in Africa?

     09 September 2015 Mark Hollis

     Governments in the region are increasingly working together to harmonize regulatory approvals

     

154. Has the economic downturn endangered governments' ability to pay for new treatments in Europe?

     03 September 2015 Floriane Reinaud

     Can European governments fund new and innovative pharmaceuticals given their growing debt?

     

155. Diabetes Foreningen publishes major impact study on diabetes related costs in Denmark

     27 August 2015 Eoin Ryan

     Diabetes-related social and economic costs amounted to DKK31.8 billion (USD4.75 billion) in 2011, corresponding to DKK107,000 (USD16,000) per...

     

156. Our burgeoning understanding of payer perspectives on relative effectiveness

     25 August 2015 Cameron Lockwood

     A close look at the market-specific differences in terms of how payers would like to see manufacturers address the REA gap

     

157. Impact of the Tianjin explosion on the global pharmaceutical industry

     19 August 2015 Sophie Cairns

     IHS Life Sciences expects the explosion to cause significant disruption to the shipment of non-time-sensitive pharmaceutical exports

     

158. Mixed feelings for mixed billing – the case in Japan.

     17 August 2015 Cecilia Chui

     What gets covered when a patient receives both insured and uninsured treatments in the same medical care series?

     

159. HTA makes headway in the Kingdom: The restructuring of Saudi's Ministry of Health in context

     31 July 2015 Cameron Lockwood

     Understanding what's at stake, and behind, the changes within the Saudi MOH

     

160. A national cancer biomarker platform in Spain: When will it become a reality?

     28 July 2015 Tania Rodrigues

     The quest to dramatically change the molecular diagnostic landscape and ultimately provide a global vision of cancer treatment in Spain.

     

161. Transforming the Brazilian domestic pharma industry through PDPs

     23 July 2015 Angelica Kershaw

     According to the MoH, with the implementation of these partnerships the Brazilian government has achieved BRL2.5 billion (USD782.2 million) in...

     

162. Maintaining focus in access to ARV medicines

     21 July 2015 Mark Hollis

     Does the UNAIDS report whitewash over the very real funding crisis facing HIV treatment programs?

     

163. Will Eurasia be a new single drugs market?

     16 July 2015 Kavita Rainova

     Do these new documents point to a single drugs market within the Eurasian Economic Union (EEU)?

     

164. The price tag of obesity: $63.49/lb. per year

     14 July 2015

     Using our disease prevention microsimulation model to understand the true burden of disease

     

165. Thai government's move to curb medicine prices – what does it mean for multinational pharma?

     08 July 2015 Sophie Cairns

     Thailand's battle against runaway pharmaceutical prices.

     

166. South Korea: Healthcare and TPP prospect

     06 July 2015 Zhang, Jing

     A closer look at South Korea's healthcare economy

     

167. Sovaldi casts a shadow on US pricing and reimbursement environment – it could have been worse

     30 June 2015 Milena Izmirlieva

     Are there signs of actual changes in the United States P&R environment as a result of the 'Sovaldi Effect'?

     

168. As Gilead's HCV patents come under threat across the world should Pharma be worried?

     26 June 2015 Margaret Labban

     A global perspective on Gilead's pricing strategy. The Sovaldi debate continues

     

169. Ukraine: Chaos continuing within country's healthcare system?

     22 June 2015 Kavita Rainova

     A closer look at the Ukrainian healthcare system amidst the country's ongoing turmoil

     

170. Sweden publishes more details on modifications of its VBP system. Years of ambiguity coming to an end?

     17 June 2015 Maria McGee

     Sweden looks to reform its pricing model.

     

171. Will the latest UK-lead review into antimicrobial resistance help revive greater interest from pharma?

     14 June 2015 Tania Rodrigues

     Is global action needed to curb wide-spread use of antibiotics and the development of drug-resistant bacteria?

     

172. Market access in the Middle East

     05 June 2015 Cecilia Chui

     Tracking shifts in MENA healthcare systems

     

173. M&A makes its way to MENA: Valeant's rumored talks with Amoun in context

     02 June 2015 Cameron Lockwood

     The Middle East and North Africa is a region once again on the radar, following recent rumours that Valeant is considering a bid for Egypt's...

     

174. Venezuelan health system in intensive care

     27 May 2015 Angelica Kershaw

     A close look at the drug shortages in Venezuela

     

175. Communicating the spreadsheets: Evolving regulations over how to present health economic data to payers

     19 May 2015 Gustav Ando

     Insights on regulations from #ISPORPhila

     

176. Learning to Reduce Waste, Variation and Inefficiency – the Healthcare Learning Experience at #ISPORPhila

     18 May 2015 Gustav Ando

     insights from #ISPORPhila 2015

     

177. Europe's biosimilars market – the next three years will be crucial

     14 May 2015 Brendan Melck

     Insights from the European Generics Association's (EGA) annual biosimilars conference.

     

178. What if a universal public drug plan were to become a reality in Canada?

     12 May 2015 Margaret Labban

     On average, an estimated CAD7.3 billion (USD5.95 billion) in savings could be achieved in Canada through a universal drug plan.

     

179. IHS @ ISPOR – Please visit us at Table TT2 on the 5th floor

     07 May 2015 Gustav Ando

     IHS Life Sciences will be at ISPOR May 16-20

     

180. The quiet death of universal health insurance in India

     05 May 2015 Mark Hollis

     A look at the changing healthcare policy in India. Is it the end of the move towards universal coverage?

     

181. The Sovaldi anti-diversion debate: Placing Gilead's access initiatives under the spotlight

     29 April 2015 Cameron Lockwood

     A look at the "barriers to access" for Sovaldi

     

182. When do price changes occur for branded pharmaceuticals in the top 5 EU markets?

     26 April 2015 Floriane Reinaud

     IHS Life Sciences analysed price changes for innovative drugs approved by the European Medicines Agency (EMA) that were priced in 2009 and afterwards....

     

183. WHO sets new malaria treatment guidelines as GSK publishes additional data on candidate malaria vaccine

     24 April 2015 Mark Hollis

     In the lead-up to World Malaria Day, the World Health Organization has published new guidelines on the clinical management of malaria. In addition...

     

184. Is China's mounting red tape in the pharma sector just disguised protectionism?

     23 April 2015 Sophie Cairns

     A look at China's CFDA new regulations on far-flung corners of its pharmaceutical sector: multi-regional clinical trials, biosimilars, drug evaluation...

     

185. Health Impact Assessment for analysis of energy policy: Ensuring the big picture is not missed

     21 April 2015 April Semilla

     The importance of Health Impact Assessments (HIA) as a means of adding unique insights to a one dimensional analysis

     

186. What's next for pharmaceutical M&A activity?

     15 April 2015 Praful Mehta

     A look at M&A activity for the industry

     

187. Sustainability of Colombian healthcare reform

     13 April 2015 Angelica Kershaw

     A deeper look at Colombia's "healthcare statutory law

     

188. Polish pharma industry furious over MoH's warning to HTA agency

     09 April 2015 Brendan Melck

     Poland's pharmaceutical industry has reacted with strong condemnation to a letter sent by the deputy health minister to the country's health...

     

189. Repatha versus Praluent: Will the approval of PCSK9 inhibitors trigger a new price war in the US?

     06 April 2015 Federica Benassi

     Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab) are expected to become the next cardiovascular blockbusters able to...

     

190. Sweden draws on Denmark´s experiences to reduce cancer care inequalities

     02 April 2015 Maria McGee

     The Swedish government has announced it is drawing on Danish experiences to improve cancer care by introducing standardised cancer care pathways...

     

191. The impact of HTA decisions on market access of oncology drugs in Canada

     31 March 2015 Margaret Labban

     The pricing and reimbursement (P&R) landscape for pharmaceuticals is gradually changing in Canada, particularly as the provinces have banded...

     

192. The impact of pharmaco-economic analyses and efficiency opinions in France

     25 March 2015 Anne-Charlotte Ackermann

     We examine how the new pharmaco-economic evaluations impact market access conditions for innovative medicines in France.

     

193. The Philippines: To TPP or not to TPP?

     23 March 2015 Zhang, Jing

     A close look at the the outlook for the Philippines and the pros and cons of joining the Trans-Pacific Partnership (TPP)

     

194. Cancer Drugs Fund: The dilemma of striking a balance between drugs' accessibility and cost sustainability continues

     16 March 2015 Kavita Rainova

     As of 12 March, some of the drugs that were previously funded through the Cancer Drug's Fund (UK) have been de-listed.

     

195. AAMC Projects Physician Shortage in the United States

     06 March 2015 Will Iacobucci

     The Association of American Medical Colleges (AAMC), an organization that represents the accredited medical schools and teaching hospitals in...

     

196. IHS examines the global experience with risk sharing agreements in recent conference presentation

     03 March 2015 Milena Izmirlieva

     Learn more about the trends in risk sharing agreements (known as patient access schemes (PAS) in some markets) and the growing prevalence of...

     

197. Middle East: The new promised land for pharma?

     27 February 2015 Cecilia Chui

     Economically, the Middle East (ME) is well positioned to be the one of next growth engine of global pharmaceutical sales: several countries in...

     

198. The fifty shades of grey of IRP

     20 February 2015 Cameron Lockwood

     The fifty shades of grey of international reference pricing (IRP): it's a connection probably lost on the majority of those flocking to see...

     

199. Revolutionary medicine: Eye on Cuba's pharma industry development following plans to normalise US-Cuba diplomatic relations

     17 February 2015 Angelica Kershaw

     An improvement in relations offers the potential to open a new era in the Cuban pharma industry.

     

200. Intra-country tiered pricing strategies: Let's get going

     09 February 2015 Marinoni, Gaelle

     Last year, when I shared some of our research findings on global pharmaceutical tiered pricing strategies, I highlighted the acute need for further...

     

201. The economics of Ebola vaccine production

     05 February 2015 Mark Hollis

     In the historic surroundings of the UK Houses of Parliament a group of leading vaccine experts and representatives of the pharmaceutical industry...

     

202. SiNATs in Portugal: True HTA reform or just another acronym?

     02 February 2015 Tania Rodrigues

     The SiNATS reform represents a significant structural reform to the way health technologies will be evaluated in Portugal.

     

203. The price of Sovaldi in France: Goodwill or a strategic move?

     30 January 2015 Choukri Genane

     With a target population for Sovaldi representing 70,000 to 80,000 patients in France, the potential cost for the health insurance system is...

     

204. Key drivers for the industry in 2015

     27 January 2015 Gustav Ando

     IHS Life Science team provides a look atthe top drivers for the industry in 2015

     

205. Therapeutic positioning reports in Spain: More doubts and questions

     21 January 2015 Tania Rodrigues

     The main aim of this collaborative IPT model is to assist with pharmaceutical pricing and reimbursement (P&R) decisions. Published on the Spanish...

     

206. EMA policy on clinical trials data: What are the main changes?

     15 January 2015 Federica Benassi

     On January 1, 2015, the European Medicines Agency (EMA) started to proactively publish clinical data concerning applications for centralised...

     

207. Greek pharma industry continues to be caught in austerity crosswind

     12 January 2015 Brendan Melck

     Greek pharmaceutical companies have had a tough year in 2014. The year started with the implementation of a new law on pharmaceutical pricing...

     

208. The war against superbugs intensifies

     06 January 2015 Margaret Labban

     US President Barack Obama issued an executive order and national strategy to combat antibiotic resistance in September 2014, almost exactly a...

     

209. Drug companies face challenges to expanding tiered pricing

     02 January 2015 Gaelle Marinoni

     Tiered drug pricing-in which pharmaceutical companies charge different prices across markets and market segments-is poised for expansion into...

     

210. Bill on seeking licences for drug following patent expiry raises questions over off-label use of drugs in the UK

     29 December 2014 Kavita Rainova

     In early November a bill was put in front of the British parliament, for second reading, proposing that new licences should be sought by the...

     

211. China's drug price deregulation

     19 December 2014 Sophie Cairns

     Last month, media reports surfaced over a missive that China's central pricing authority had issued to provincial pricing authorities during...

     

212. Parallel-export bans: Member states in collision course with EU regulations?

     11 December 2014 Brendan Melck

     An increasing number of new EU member states in central and south-eastern Europe are introducing new legislation to allow restrictions and bans...

     

213. IMPROVE-IT becomes the first trial to prove the LDL Hypothesis with a non-statin drug

     09 December 2014 Margaret Labban

     The highly anticipated trial results have reaffirmed the "LDL hypothesis" and offer a particularly positive outlook for present and future LDL...

     

214. Adaptive licensing and early access to innovation: The views from ISPOR Europe annual meeting

     03 December 2014 Milena Izmirlieva

     For pharma manufacturers early access to innovation should generally translate into early patient access and earlier revenues than if a company...

     

215. EMA enables use of foreign reference product to facilitate biosimilars development in the EU

     01 December 2014 Federica Benassi

     With the recent publication of the revised overarching guideline on biosimilar medicines, the European Medicines Agency (EMA) has formally introduced...

     

216. Fresenius terminates deal with Russia's Binnopharm: A sign of what is to come?

     26 November 2014 Kavita Rainova

     The recent deal termination has refocused attention on the overall political, social and economic climate in Russia, as well as specific pharmaceutical...

     

217. Current prospective and potential future evolution of HTA cooperation at the EU level

     24 November 2014 Federica Benassi

     I recently attended the conference HTA 2.0 Europe – Teaming Up for Value organised by EUnetHTA in Rome. here are some thoughts and take-aways...

     

218. Market access risk: An update to the changing market access landscape

     21 November 2014 Praful Mehta

     Using a risk ratings framework to help pharmaceutical companies better navigate and understand the changing market access landscape by quantifying...

     

219. The role of orphan and specialty drugs in US hospital costs

     19 November 2014 Cameron Lockwood

     A closer look at orphan drugs, specialty drugs and rising costs in US hospitals

     

220. The challenges for patient access in Central and Eastern Europe discussed at ISPOR

     17 November 2014 Milena Izmirlieva

     At the ISPOR 17th Annual European Congress earlier this week, pricing and reimbursement challenges in Central and Eastern European (CEE) countries...

     

221. How do we quantify 'hysteria' in vaccine pricing? Thoughts from #ISPORAMST

     12 November 2014 Mark Hollis

     I'm at the ISPOR Europe 2014 (#isporamst2014) meeting, and an issue that keeps cropping up is vaccine pricing. This is also something that I...

     

222. AMNOG and Sovaldi – no change, for now at least

     11 November 2014 Brendan Melck

     AMNOG - and the system of early benefit assessment of new innovative drugs which it introduced - remains the most widely-discussed aspect of...

     

223. ISPOR Europe Number 17 – How Will Payers Pay For Healthcare in the Future?

     10 November 2014 Gustav Ando

     The 17th European Congress of ISPOR kicked off in a combative fashion this morning with a plenary session devoted to how to create sustainable...

     

224. See you at ISPOR Amsterdam next week. IHS booth 809!

     06 November 2014 Gustav Ando

     The IHS Life Sciences team is pleased to announce that we will have a strong presence at the ISPOR 17th European Congress in Amsterdam, 8-12...

     

225. Bulgaria's recent IRP change: A testament to the impracticality of seeking to reference discounted prices

     04 November 2014 Milena Izmirlieva

     In a comparatively unexpected move, Bulgaria's caretaker government has decided to introduce significant changes in the country's international...

     

226. World's largest payer-industry partnership? A case against unilateral cost-containment efforts

     27 October 2014 Margaret Labban

     Canada's unprecedented "18 at 18%" national generic drug pricing agreement is set to save the healthcare system billions. On 1 April ...

     

227. 10 years since the first biosimilar: FDA finally paves the way for approval of first biosimilar in the US

     23 October 2014 Milena Izmirlieva

     This month marks ten years since our same day analysis service was the first to report on the world's first biosimilar approval in Australia....

     

228. Will a new tax and informal IRP network help France negotiate a lower price for Sovaldi?

     20 October 2014 Federica Benassi

     While an increasing number of new HCV treatments gain approval for marketing authorisation in Europe, EU member states are looking at ways to...

     

229. Lack of vaccine or lack of beds leading to the growing outbreak of Ebola?

     16 October 2014 Mark Hollis

     Earlier this week, I appeared in CNBC to discuss the growing challenges around treating and containing Ebola. The World Health Organization...

     

230. The end of transatlantic M&A in pharma? The clampdown on tax inversion and implications for pharma

     07 October 2014 Gustav Ando

     As we discussed in a blog earlier this year, it was clear early on this year that 2014 will be remembered as the year in which M&A activity ret...

     

231. NICE eschews Value-Based Assessment for now: Are we ready for consensus?

     26 September 2014 Cameron Lockwood

     Sometimes standing still is the best way to move forward. Just ask the UK's National Institute for Health and Care Excellence (NICE), which this...

     

232. No pharmaceuticals import ban in Russia, but restricted admission to government procurement system sends mixed messages

     22 September 2014 Kavita Rainova

     In the last few days, various government officials in Russia have been issuing statements saying that the import of pharmaceuticals will not...

     

233. (Having it) Made in China: The Chinese CRO market

     04 September 2014 Sophie Cairns

     When entering China, test your drugs as the Chinese do. That may not be as catchy as the saying about Romans, but it's a rule that every company...

     

234. Tiered pricing strategies: Where next?

     21 August 2014 Marinoni, Gaelle

     Tiered pricing is a commercial strategy that consists of charging different prices to different markets or market segments. In pharma, tiered...

     

235. Ebola – What's the Pipeline?

     14 August 2014 Gustav Ando

     As the 2014 West Africa Ebola virus outbreak claims its thousandth victim, many questions are being asked over how the disease can be contained...

     

236. Spain creates legal uncertainty over biosimilars

     01 August 2014 Angelica Kershaw

     From a government perspective, the potential benefits of biosimilars are pretty clear: they offer great potential to improve healthcare access...

     

237. Acute cures for chronic diseases: Are new financing and messaging models needed?

     31 July 2014 Tericke Blanchard

     The development of short-term therapies that can cure life-threatening diseases, versus chronic treatments that manage the condition, are driving...

     

238. Ukraine's current healthcare market: Uncertainty, pricing reforms, and calls for the health minister's resignation

     28 July 2014 Kavita Rainova

     Over the past few weeks reports have been surfacing in the Ukrainian media over calls for the resignation of Ukraine's current Health Minister...

     

239. PD-1 inhibitors – making immuno-oncology mainstream?

     23 July 2014 Margaret Labban

     The world's first Programmed cell death 1 (PD-1) inhibitor was approved in Japan this month for the treatment of advanced melanoma. This novel...

     

240. New Greek health minister faces important challenges in drug P&R policy

     21 July 2014 Brendan Melck

     Greece's new health minister, Makis Voridis, inherits the same overriding issue in the area of pharmaceutical policy as his predecessor - ......

     

241. Are the amendments to Russia's drug circulation law on the way to becoming reality?

     14 July 2014 Kavita Rainova

     Early this month it was reported that the amendments to Russia's drug circulation law, Federal law FZ:61, were finally passed to the country's...

     

242. Where was rising health expenditure in the Indian government budget?

     11 July 2014 Mark Hollis

     For some, any hope of a change in pharmaceutical and healthcare policy from India's much extolled new government were dashed the moment the new...

     

243. Are we nearing the end of gloom and doom for the pharma industry: Insights from the EGA meeting

     10 July 2014 Milena Izmirlieva

     I had the pleasure of attending the European Generic Medicines Association (EGA) annual meeting a few days ago and was struck by how little has...

     

244. Why is the Lucentis-Avastin case back in the spotlight?

     07 July 2014 Federica Benassi

     Is Avastin as safe and effective as Lucentis in an ophthalmology setting? In recent years, many countries have evaluated potential risks posed...

     

245. How to train your data – integrating comparative effectiveness research (CER) into Big Data: Insights from ISPOR

     23 June 2014 Tericke Blanchard

     The role of big data in healthcare decision making was the central theme at ISPOR's annual meeting in Montreal earlier this month. The greater...

     

246. Life after the patent cliff: What's next for generics?

     20 June 2014 Milena Izmirlieva

     As Indian generics producer Dr. Reddy's announced yesterday that they want to boost their involvement in proprietary drugs and biosimilar drugs...

     

247. Flexible pricing in the UK: Where is industry?

     16 June 2014 Cameron Lockwood

     If you build it, they will come," a voice once whispered to Kevin Costner in Field of Dreams. (Technically that's a misquote, but since ...

     

248. Adaptive Licensing + Flexible Pricing = Adaptive Pricing?

     13 June 2014 Marinoni, Gaelle

     The European Medicines Agency (EMA) recently launched an adaptive licensing pilot project, which was hailed by the Agency as an initiative "to...

     

249. How much weight do Canada's HTA assessments carry, and could value-based tiered formularies gain traction in the US – some thoughts from ISPOR

     04 June 2014 Margaret Labban

     Negative recommendations don't always preclude market access in Canada I've been covering The Canadian Agency for Drugs and Technologies in ......

     

250. Big Data, Health Economics and Pricing & Reimbursement

     03 June 2014 IHS Markit Life Sciences Expert

     From fraud protection to online advertising, "big data" plays a large role behind the scenes of all of our day-to-day lives. References to ......

     

251. IHS at ISPOR Montreal, 2-4 June 2014. Visit us at Table 136!

     30 May 2014 Gustav Ando

     The IHS Life Sciences team is pleased to announce that we will again have a strong presence at the ISPOR 19th Annual International Meeting in...

     

252. Will payer alignment across sectors in Sweden lead to harmonisation of drug P&R procedures?

     21 May 2014 Maria McGee

     Having covered drug P&R developments in the Nordic markets here at IHS and with my participation in this recent study on flexible pricing, I h...

     

253. M&A, Reputational Risks and Pharmaceutical Pricing In Light of Pfizer's Bid for AstraZeneca

     09 May 2014 Gustav Ando

     There has been a wildfire of criticism from many sectors over Pfizer's proposed record bid to acquire AstraZeneca over the last couple of weeks....

     

254. Value Based Assessment: Two new modifiers to NICE's assessment method, but no price setting agenda

     28 April 2014 Kavita Rainova

     The United Kingdom's National Institute of Care Excellence (NICE) has recently issued its document on Value based assessment (VBA) for consultation....

     

255. Pharma adjusts to patent expiries, price cuts and pipeline setbacks...is a mega-merger frenzy returning?

     22 April 2014 Gustav Ando

     Easter bunnies hunting for the pipeline eggs The Easter weekend of 2014 will be remembered in the pharmaceutical industry as a moment where several...

     

256. Is Sovaldi the new Lipitor?

     16 April 2014 Margaret Labban

     Pfizer's Lipitor (atorvastatin), a small-molecule drug prescribed to lower cholesterol, set a world record in 2006 by generating $13.7 billion...

     

257. Is real-world data a market access hurdle or facilitator?

     08 April 2014 Marinoni, Gaelle

     The IHS Life Sciences team is currently undertaking research on the concept of flexible pricing. Introduced notably in the UK Pharmaceutical...

     

258. Poland's Reimbursement Act – A promise only partially delivered

     26 March 2014 Brendan Melck

     At the end of last year, the Polish Ministry of Health (MoH) published its summary of the achievements of the Reimbursement Act. The wide-ranging...

     

259. Norway's discount on infliximab: A litmus test for biosimilar expansion in Europe?

     20 March 2014 Federica Benassi

     Looking at recent developments in the European pharmaceutical markets, biosimilars seems to have a major potential for growth - and conversely...

     

260. Measuring the effectiveness of risk minimisation: A growing driver of post-authorisation studies in Europe

     17 March 2014 Cameron Lockwood

     Just recently, the EMA published its first summary of a risk-management plan for a centrally authorised product, Neuraceq for PET imaging in...

     

261. IHS Healthcare and Pharma is now IHS Life Sciences

     11 March 2014 Gustav Ando

     The IHS Healthcare and Pharma team is happy to announce that we are now IHS Life Sciences. Our new group name better conveys the breadth and...

     

262. A look into JAK Inhibitor development: Has the interest diminished post-fedratinib?

     03 March 2014 Tania Rodrigues

     As Sanofi's discontinuation of fedratinib for myelofibrosis (MF) in Phase III trials grabbed the headlines at the American Haematology Society...

     

263. Delisting products from national reimbursement lists: A dilemma to payors and a potential threat to Industry and patients

     27 February 2014 Maria McGee

     Having attended the LSE Risk Sharing and Managed Entry Agreements (MEA) Summit in London on 14 February, I was struck by the wide-spread audience...

     

264. The dark side of Obamacare: The unintentional outcomes

     24 February 2014 Margaret Labban

     Obamacare may reduce labour force participation The Congressional Budget Office (CBO)'s latest Budget and Economic Outlook forecast has come...

     

265. The end of the pharma emerging market strategy?

     18 February 2014 Mark Hollis

     Recent newspaper headlines have been full of doom and gloom over the state of emerging market economies. From Turkey, to South Africa, and Argentina...

     

266. Drug patent expirations 2014

     13 February 2014 Gustav Ando

     2014 is shaping up to be among the quietest years in recent memory as the patent cliff reaches its end - although there will be a notable spike...

     

267. Worst-case scenarios emerging in the French drug evaluation reform? ITR versus SMR/ASMR

     06 February 2014 Marinoni, Gaelle

     I have got news in relation to the French pricing and reimbursement (P&R) reform, which is meant to see the replacement of the country's SMR/ASMR......

     

268. Pharma's key drivers for 2014

     04 February 2014 Gustav Ando

     In many ways, 2014 has kicked off in a very similar way to how 2013 started for the global pharmaceutical industry: with a major setback. In...

     

269. Collaborations between foreign and domestic pharma companies in Russia mark the start of a trend

     29 January 2014 Kavita Rainova

     Over the past few months, there has been a steady inflow of news about collaboration between foreign pharma companies and Russian firms, along...

     

270. Price cuts in lieu of IPR and back order agreements: Is the Swedish consensus approach to the pharma industry under threat?

     27 January 2014 Maria McGee

     Pharmaceutical companies in Sweden currently have a number of agreements with the government that focus on how the industry is regulated. What...

     

271. Pre-AMNOG benefit assessments scrapped, but austerity persists in Germany's new coalition

     20 January 2014 Brendan Melck

     Germany's new coalition government has concluded its coalition agreement. It includes some important plans relating to public pharmaceutical...

     

272. The US: Update on the economy and healthcare

     14 January 2014 Jing Zhang

     As we begin the new year, let's take some time to look at what we expect to happen on the economic front -- for the US in general and then in...

     

273. Greece: New P&R amendment sets off political storm

     08 January 2014 Brendan Melck

     The legal amendment passed by the Greek parliament on 27 November, which is set to introduce IRP and new maximum price thresholds for off-patent...

     

274. Is the US fully prepared for major changes under Obamacare in 2014?

     29 December 2013 Margaret Labban

     The US healthcare system is going through one of the biggest overhauls in its history. Provisions mandating healthcare insurance to all Americans...

     

275. CANMab gains approval in India: Another interesting turn for trastuzumab

     22 December 2013 Cameron Lockwood

     With the recent announcement from Mylan and Biocon that their non-innovator biologic version of Herceptin has received approval in India for...

     

276. The Brazilian Drug Funding Process: Is there Order and Progress?

     18 December 2013 Tania Rodrigues

     As I sip coffee from the mug with the "Order and Progress (Ordem e Progresso, in Portuguese)" motto national flag of Brazil, which I got in Rio......

     

277. Will EUnetHTA's HTA tools translate into practice at national level?

     16 December 2013 Maria McGee

     When I attended ISPOR's 16th Annual European Congress, in Dublin, earlier this month I attended an interesting discussion on EUnetHTA. The deputy...

     

278. Downward price pressure in CEE countries – too far, too soon?

     11 December 2013 Brendan Melck

     In the four countries of central and eastern Europe (CEE) that make up the so called Visegrad 4 group - Poland, Hungary, Slovakia and the Czech...

     

279. Risks for pharma in the aftermath of San Francisco's Proposition D, allowing direct price negotiations for pharmaceuticals

     09 December 2013 Milena Izmirlieva

     On 5 November, San Francisco voters approved a measure requiring the city to directly negotiate drug prices with pharmaceutical companies. The...

     

280. Statins controversy in the US: What do the new cholesterol guidelines mean?

     03 December 2013 Praful Mehta

     The American Heart Association (AHA) and American College of Cardiology (ACC) have again landed themselves in a huge controversy. Earlier this...

     

281. France's Social Security Finance Bill 2014: What changes may occur in the French pharma market?

     02 December 2013 Federica Benassi

     Among the many cost containment initiatives in healthcare around the world in recent years, France's Social Security Finance Bill (PLFSS) for...

     

282. A new PPRS in the UK: What does it bring?

     26 November 2013 Kavita Rainova

     Earlier this month, following months of wait and speculation, the UK Department of Health (DH) and the pharma industry announced the successor...

     

283. Value-based pricing: What should we expect based on ISPOR discussions?

     25 November 2013 Milena Izmirlieva

     Value-based pricing for pharmaceuticals, or VBP, was due to be introduced in the United Kingdom for newly-approved NCEs and new indications starting...

     

284. Why isn't South Africa the new India for pharma?

     20 November 2013 Mark Hollis

     South Africa's got a lot going for it, great beaches, sunshine (important to us Brits), plentiful wine. But what it doesn't have is a significant......

     

285. EU Tobacco Products Directive: A bittersweet victory for public health?

     18 November 2013 Federica Benassi

     Figures from the European Commission estimate that tobacco is responsible for 700,000 deaths every year in Europe. Meanwhile, according to the...

     

286. Unravelling the international reference pricing conundrum: Next threats, next steps

     12 November 2013 Marinoni, Gaelle

     International reference pricing (IRP) is going global. Think about it. Is this a fact, a threat, or a mix of both? After spending the last few...

     

287. Early days, early dialogue with payers and regulators--a useful waste of time?

     05 November 2013 Gustav Ando

     Fans of the TV series South Park may be familiar with the appearance of the satirical "Captain Hindsight", a superhero who does not help people......

     

288. Increased demand for medical specialists in the United States: How an aging population accompanied by a growing disease burden will impact the demand for healthcare services

     04 November 2013 IHS Markit Life Sciences Expert

     While the aging of the "baby boomer" population in the U.S. and the associated implications for increased healthcare costs have received ...

     

289. Raised political focus on antimicrobial resistance - sufficient to incentivize Industry?

     04 November 2013 Maria McGee

     In March of this year, we published an in-depth analysis on AMR in a special report titled, "Are we losing the fight against antimicrobial ......

     

290. IHS at ISPOR Dublin, 2-6 November 2013. Visit us at booth 117!

     31 October 2013 Gustav Ando

     The IHS Healthcare & Pharma team is pleased to announce that we will again have a strong presence at the ISPOR 16th European Congress in Dublin...

     

291. The principles of HTA in Ukraine: A presentation at the Ukrainian Pharmaceutical Forum

     29 October 2013 Milena Izmirlieva

     Today, I had the privilege of making a presentation about health technology assessment (HTA) to an audience of pharmaceutical industry professionals...

     

292. Over USD 1 billion worth of investments made in Ukraine's technopark: Why the interest?

     24 October 2013 Kavita Rainova

     As an analyst covering Ukraine on a daily basis I find most developments in the country focused on low-tech technologies in healthcare - such...

     

293. DPP-4 inhibitors for type-2 diabetes: The first retroactive benefit assessment completed – winners and losers

     22 October 2013 Brendan Melck

     On 1 October, the G-BA announced the completion of the first retroactive benefit assessment of a class of medicines under AMNOG. The class involved...

     

294. International reference pricing: Connecting the dots

     18 October 2013 Gustav Ando

     The late CEO of Apple, Steve Jobs, famously quipped that "you can't connect the dots looking forward - you can only connect them looking ...

     

295. Is crowd funding an alternative answer to the African pharmaceutical investment conundrum?

     09 October 2013 Mark Hollis

     I attended the African Pharmaceutical Summit, held recently in Tunisia, and noted that delegates appeared to rally behind the notion of pharmaceutical...

     

296. Relvar Ellipta: Payers now in sight

     07 October 2013 Cameron Lockwood

     GlaxoSmithKline and Theravance's Relvar Ellipta has found itself making multiple headlines lately- first as the result of a positive CHMP ......

     

297. Could the US government shutdown undermine healthcare reform in the US?

     02 October 2013 Margaret Labban

     On 1 October, health insurance marketplaces were officially launched in the US, offering affordable health care coverage to millions of uninsured...

     

298. ESC Congress 2013: What are the lessons?

     30 September 2013 Praful Mehta

     Earlier this month, the European Society of Cardiology (ESC) concluded its most prestigious event - ESC Congress 2013 - amid much fanfare. The...

     

299. Assessing market access risk: Understanding pricing, cost, and market trends webinar

     23 September 2013 Gustav Ando

     In July, IHS launched its pharmaceutical Market Access Risk Scores (MARS), which are designed to quantify the relative risks of global pharmaceutical...

     

300. Approval of the first biosimilar antibody in Europe: Why the world will be watching

     19 September 2013 Margaret Labban

     On 10 September 2013, US-headquartered biopharmaceutical firm Hospira and South-Korean partner Celltrion became the first companies to gain marketing...

     

Show More Results